We found only 4 significant results in this analysis: First, low ACSL3 expression in Naïve B cells, and low ACSL5 and ACSL6 in Naïve CD8 cells, correlated with worse patient survival outcomes, demonstrating a potential reliance on these for an effective anti‐cancer immune response (Fig. S4). This evidence concerns the gene ACSL3 and cancer.